Based upon the findings of Resolve and FLOT4 trials,neoadjuvant chemotherapy + D2 radical resection for gastric cancer has become one of the latest standard treatments.Immunotherapy of PD-1/PD-L1 monoclonal antibody has significantly improved the survival outcomes of patients with locally advanced gastric cancer.Perioperative chemoimmunotherapy could significantly boost the pathological complete response rate.The Matterhorn study has demonstrated significant short-term efficacy.However,the ATTRACTION-5 and KEYNOTE-585 studies failed to fulfill the expectations.Screening of immunodominant populations and a proper choice of chemotherapeutic regimen are two major issues of perioperative immunotherapy.
维普
万方数据